Compound Radar

Elanco Animal Health Incorporated (ELAN) Stock Analysis

Price $23.97
Market cap $11.97B
Next earnings Nov 5, 2026
Entry status Watch $21.75–$22.75

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 30
  • Profitability 50
  • Business Quality 75
  • Balance Sheet 40
  • Cash Flow 80

Why this rating?

Health 45/100 — Speculative

Strongest Cash Flow 80/100
Softest Financial Health 30/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Elanco Animal Health Incorporated (ELAN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Elanco Animal Health Incorporated 45/100 (Speculative) due to high business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Fair

Financial highlights

Valuation

  • Forward P/E 18.73
  • EV/Revenue 3.18

Profitability

  • Revenue Growth 10.2%
  • Gross Margin 55.4%
  • Operating Margin 8.6%
  • Net Margin -4.0%
  • ROE -3.0%

Financial strength

  • Cash $530.00M
  • Debt $4.23B
  • Net Cash $-3.70B
  • Free Cash Flow $284.00M
  • Current Ratio 2.05

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Elanco Animal Health Incorporated (ELAN).

View Methodology & FAQ →